Precision Cell Immunotherapy Combined With TACE in Advanced Liver Cancer

Inclusion Criteria: 1. Age 18\~65 years old, male or female; 2. Life expectancy≥6 months; 3. ECOG score: 0-3; 4. Advanced Malignancies (lung cancer, gastric cancer) were diagnosed by pathological or clinical physicians,and Diagnosis of hepatocellular carcinoma (HCC), surgery can not be performed but TACE treatment can be carried out; 5. Enough venous channel, no other contraindications to the separation and collection of white blood cells; 6. Laboratory examination: white blood cell≥3 x 10\*9/L, blood platelet count≥60 x 10\*/L, hemoglobin≥85g/L; lymphocyte count≥15%, total bilirubin≤100 mol/L; ALT and AST less than five times of the normal level; serum creatinine less than 1.5 times of the normal level； 7. Signed informed consent； 8. Women of child-bearing age must have evidence of negative pregnancy test and be willing to practice birth control after 2 weeks following the cells transfusion. Exclusion Criteria: 1. Expected Overall survival \< 3 months 2. The tumor size or quantity is not suitable for interventional treatment or portal vein tumor thrombus 3. Liver function is Childs Pugh C 4. Had received TACE therapy previously or in radiotherapy at present,or taking Sola Feeney 5. Other serious diseases:the heart,lung, kidney,digestive, nervous, mental disorders, immune regulatory diseases, metabolic diseases, infectious diseases, etc. 6. Unable or unwilling to provide informed consent, or fail to comply with the test requirements.